Clinical trial NCT06938854: Investigational Study of SWM-831 to Treat Moderate and Severely Calcified Femoropopliteal Arteries
Official title: Prospective, Multi-center, Single-arm Investigational Study of SWM-831 to Treat Moderate and Severely Calcified Femoropopliteal Arteries
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Peripheral Arterial Disease
Lead sponsor: Shockwave Medical, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Iqvia Pty Ltd
name: Massachusetts General Hospital
name: Yale University
First posted: 2025-04-22
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The objective of the study is to assess the safety and effectiveness of IVL to treat moderate and severely calcified femoropopliteal arteries, prior to DCB or stenting.
Primary purpose: TREATMENT

Brief summary: Disrupt PAD Japan is a prospective, multi-center, single-arm study of SWM-831 to treat moderate and severely calcified femoropopliteal arteries, prior to DCB or stenting.

Detailed description: Up to 60 subjects at up to 10 sites in Japan will be enrolled in the femoropopliteal clinical study with moderate and severely calcified femoropopliteal artery disease presenting with Rutherford Category 2 - 5 of the target limb.

Two additional cohorts \[Iliac and BTK (Below-the-Knee)\] will enroll a minimum of 10 and a maximum of 15 subjects each with moderate and severely calcified iliac disease with a Rutherford Category (RC) 2 - 5 and a minimum of 10 and a maximum of 15 subjects with moderate and severely calcified BTK lesions with a Rutherford Category (RC) 2 - 5 will be enrolled and followed through 12 months.

The estimated study duration for these cohorts is approximately 24 months. Study subjects will be followed through discharge, 30 days, 6, and 12 months.

Eligibility criteria: General Inclusion Criteria:

Subjects are required to meet all of the following inclusion criteria in order to be enrolled in the clinical study:

1. Subject is able and willing to comply with all assessments in the study.
2. Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and has signed the approved consent form.
3. Age of subject is ≥ 18. Note: If a subject is under 20 years, voluntary agreement shall be obtained from both the subject and the subject's representative or legal guardian using the written consent form.
4. Rutherford Clinical Category 2, 3, 4, or 5 of the target limb.
5. Estimated life expectancy \> 1 year.

Angiographic Inclusion Criteria:

Subjects are required to meet all of the following inclusion criteria in order to be enrolled in the clinical study. For lesion characteristics, each target lesion must meet eligibility.

1. One target lesion that is located in a native, de novo superficial femoral artery (SFA) or popliteal artery (popliteal artery extends to and ends proximal to the ostium of the anterior tibial artery). \<Not applicable to iliac or BTK cohort\>
2. Target lesion reference vessel diameter (RVD) is between 4.0 mm and 8.0 mm by investigator visual estimate. \<Not applicable to iliac or BTK cohort\>
3. Target lesion with ≥ 70% stenosis by investigator visual estimate.
4. Target lesion length is ≤ 200 mm by investigator visual estimate. Target lesion can be all or part of the 200 mm treated zone.
5. Subject has at least one patent tibial vessel on the target limb with runoff to the foot, defined as no stenosis ≥ 50%.
6. Calcification is determined to be grade 2 - 4 (unilateral calcification ≥ 5 cm, bilateral wall calcification \< 5 cm, and bilateral calcification ≥ 5 cm, respectively), as defined by PACSS (Peripheral Artery Calcification Scoring System). \<Not applicable to iliac and BTK cohort\>

Angiographic Inclusion Criteria specific to Iliac Arteries

1. Target lesion located in the native, de novo common or external iliac artery.
2. Target lesion reference vessel diameter (RVD) is between 5.0 mm and 10.0 mm by investigator visual estimate.
3. Evidence of PACSS calcification grade 2 - 4 and non-dilatable lesion indicating presence of calcium.

Note: Non-dilatable lesion requires attempted treatment with PTA during the index procedure with residual stenosis ≥ 50% and no serious angiographic complication.

Angiographic Inclusion Criteria specific to BTK Arteries

1. Target lesion from the native, de novo distal segment of the popliteal artery to the ankle joint.
2. Target lesion reference vessel diameter (RVD) is between 2.0 mm and 4.0 mm by investigator visual estimate.
3. Evidence of PACSS calcification grade 2 - 4 and non-dilatable lesion indicating presence of calcium.

Note: Non-dilatable lesion requires attempted treatment with PTA during the index procedure with residual stenosis ≥ 50% and no serious angiographic complication.

General Exclusion Criteria

Subjects who meet any of the following exclusion criteria may not be enrolled in the study:

1. Rutherford Clinical Category 0, 1 and 6.
2. Subject has known or suspected active infection evidenced by WBC \> 14.0 (14000/mm3) within 14 days prior to index procedure.
3. Previous or planned target limb major amputation (above the ankle).
4. History of prior endovascular or surgical procedure on the index limb within the past 30 days or planned within 30 days of the index procedure.

   Note: Inflow treatment of non-target lesions is allowed provided successful treatment.
5. Subject in whom antiplatelet or anticoagulant therapy is contraindicated.
6. Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.
7. Subject has known allergy to urethane, nylon, or silicone.
8. History of myocardial infarction within 60 days prior to enrollment.
9. History of stroke within 60 days prior to enrollment.
10. History of thrombolytic therapy within two weeks prior to enrollment.
11. Subject has acute or chronic renal disease with creatinine \> 2.5 mg/dL, unless on dialysis.
12. Subject is pregnant or nursing.
13. Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.
14. Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.
15. The use of specialty balloons, re-entry or atherectomy devices.
16. Active COVID-19 or previously diagnosed COVID-19 with sequelae that could confound endpoint assessments.
17. Subject has an anticipated life span of less than one (1) year.

General Exclusion Criteria specific to BTK Arteries

1. Subjects with osteomyelitis or deep soft tissue infection in the target limb.
2. Acute limb ischemia (of either leg).
3. Occlusion of all the inframalleolar outflow arteries/vessels (i.e., desert foot) in the target limb.

Angiographic Exclusion Criteria

Subjects who meet any of the following exclusion criteria may not be enrolled in the study:

1. In-stent restenosis within 10 mm of the target lesion.
2. Lesion within 10 mm of the ostium of the SFA or within 10 mm proximal to the anterior tibial artery ostium. \<Not applicable to iliac or BTK cohort\>
3. Evidence of aneurysm or thrombus in target vessel.
4. No calcium or mild calcium in the target lesion by PACSS.
5. Target lesion within native or synthetic vessel grafts.
6. Subject has significant stenosis (≥ 50% stenosis) or occlusion of inflow tract before target treatment zone (e.g., iliac or common femoral) not successfully treated.
7. Failure to successfully treat significant distal non-target lesions, if treated prior to target lesion. Successful treatment is defined as obtaining \< 50% residual stenosis with no serious angiographic complications (e.g., embolism).
8. Failure to successfully cross the guidewire across the target lesion; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations.

Angiographic Exclusion Criteria specific to Iliac Arteries

1.Target lesion with any aorta involvement.

Angiographic Exclusion Criteria specific to BTK Arteries

1. Failure to treat clinically significant inflow lesions in the ipsilateral iliac, femoral, or popliteal arteries with \< 30% residual stenosis, and no serious angiographic complications (e.g., embolism).
2. Treatment of vessels below the ankle joint.

Primary outcomes:
measure: Percentage of Subjects with Procedural Success
timeFrame: Day 0
measure: Percentage of Subjects with Procedural Success
timeFrame: Day 0
measure: Percentage of Subjects with Procedural Success
timeFrame: Day 0
Secondary outcomes:
measure: Rate of ≥ grade D dissections, perforation, distal embolization, slow flow or acute vessel closure
timeFrame: Day 0
measure: Residual stenosis < 50% without ≥ grade D dissections
timeFrame: Day 0
measure: Residual stenosis < 30% without ≥ grade D dissections
timeFrame: Day 0
measure: Number of participants with freedom from clinically-driven target lesion revascularization (CD-TLR) CEC adjudicated and freedom from restenosis as determined by duplex-derived peak systolic velocity ratio (PSVR) ≤ 2.4, assessed by the DUS core lab.
timeFrame: At 6 months and 12 months post-procedure
measure: Number of participants with Major Adverse Event
timeFrame: At 30 days, 6 months and 12 months post-procedure
measure: Number of participants with change in Ankle brachial index (ABI) or Toe brachial index (TBI)
timeFrame: At 30 days, 6 months, and 12 months post-procedure
measure: Number of participants with change in Rutherford Category
timeFrame: At 30 days, 6 months, and 12 months post-procedure
Other outcomes:
Locations:
city: Chiba
country: Japan
facility: Tokyobay Urayasu Ichikawa
city: Ehime
country: Japan
facility: Matsuyama Red Cross Hospital
city: Fukuoka
country: Japan
facility: Kokura Memorial Hospital
city: Hokkaido
country: Japan
facility: Caress Sapporo Tokeidai Memorial Hospital
city: Kanagawa
country: Japan
facility: Tokushukai Shonan Kamakura General Hospital
city: Miyagi
country: Japan
facility: Sendai Kousei Hospital
city: Nara
country: Japan
facility: Nara Medical University Hospital
city: Osaka
country: Japan
facility: Osaka International Medical & Science Center Daini Osaka Police Hospital
city: Tokyo
country: Japan
facility: Toho University Ohashi Medical Center
Study officials:
References: